You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells

Article info

Article menu

Download PDFPDF

Research Article
Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells

Authors

  • Anandani Nellan Department of PediatricsUniversity of Colorado Anschutz Medical Campus Aurora CO USA Morgan Adams Foundation Pediatric Brain Tumor Research ProgramChildren’s Hospital Colorado Aurora CO USA PubMed articlesGoogle scholar articles
  • Christopher Rota Division of Medical Sciences, Harvard Medical SchoolHarvard University Boston MA USA PubMed articlesGoogle scholar articles
  • Robbie Majzner Division of Pediatric Hematology and Oncology, Department of PediatricsStanford University Stanford CA USA PubMed articlesGoogle scholar articles
  • Cynthia M. Lester-McCully Pediatric Oncology Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Andrea M. Griesinger Department of PediatricsUniversity of Colorado Anschutz Medical Campus Aurora CO USA Morgan Adams Foundation Pediatric Brain Tumor Research ProgramChildren’s Hospital Colorado Aurora CO USA PubMed articlesGoogle scholar articles
  • Jean M. Mulcahy Levy Department of PediatricsUniversity of Colorado Anschutz Medical Campus Aurora CO USA Morgan Adams Foundation Pediatric Brain Tumor Research ProgramChildren’s Hospital Colorado Aurora CO USA PubMed articlesGoogle scholar articles
  • Nicholas K. Foreman Department of PediatricsUniversity of Colorado Anschutz Medical Campus Aurora CO USA Morgan Adams Foundation Pediatric Brain Tumor Research ProgramChildren’s Hospital Colorado Aurora CO USA PubMed articlesGoogle scholar articles
  • Katherine E. Warren Pediatric Oncology Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Daniel W. Lee Division of Pediatric Hematology and Oncology, Department of PediatricsUniversity of Virginia PO Box 800386 22908 Charlottesville VA USA PubMed articlesGoogle scholar articles
  1. ↵a anandani.nellan{at}ucdenver.edu
  2. ↵b christopher_rota{at}g.harvard.edu
  3. ↵c rmajzner{at}stanford.edu
  4. ↵d mccullyc{at}mail.nih.gov
  5. ↵e andrea.griesinger{at}ucdenver.edu
  6. ↵f jean.mulcahy-levy{at}childrenscolorado.org
  7. ↵g nicholas.foreman{at}childrenscolorado.org
  8. ↵h warrenk{at}mail.nih.gov
  9. ↵i 434-297-4289 dwl4q{at}hscmail.mcc.virginia.edu DWL4Q{at}virginia.edu
View Full Text

Citation

Nellan A, Rota C, Majzner R, et al
Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells
Journal for ImmunoTherapy of Cancer 2018;6:30. doi: 10.1186/s40425-018-0340-z

Publication history

  • Received January 2, 2018
  • Accepted April 4, 2018
  • First published April 30, 2018.
Online issue publication 
February 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.